Josep Rodes - Cabau, M.D., of Laval University, Quebec City, Canada, and colleagues randomly assigned 171 patients
with an indication for atrial septal defect (ASD) closure and no history of migraine to receive dual antiplatelet therapy (
aspirin +
clopidogrel [the
clopidogrel group], n = 84) or single antiplatelet therapy (
aspirin + placebo [the placebo group], n = 87) for 3 months following transcatheter ASD closure.
She was diagnosed
with coronary vasospasm and treated
with diltiazem, carvedilol,
aspirin,
clopidogrel, nitroglycerin, simvastatin, and lisinopril.